Theta Burst Stimulation for Depression

(SyncT Trial)

This trial aims to understand how continuous theta-burst stimulation (cTBS) can help individuals with depression who haven't benefited from standard treatments. Researchers are exploring two hypotheses about how cTBS affects the brain's chemical messengers: one involves reducing brain cell connections using glutamate, and the other enhances the brain's natural braking system with GABA. Participants will receive cTBS combined with either one of several FDA-approved medications or a placebo to determine which approach alters brain activity. The trial seeks individuals with moderate to severe depression who have been stable on their current medications for at least a month. As an Early Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking discoveries.

No, you won't have to stop taking your current medications. The trial requires that you have a stable medication regimen for one month before and during the study.

Research has shown that continuous theta burst stimulation (cTBS), a type of transcranial magnetic stimulation (TMS), is generally safe for treating depression. Previous studies found cTBS to be safe and well-tolerated, with most participants responding well to the treatment. Some experienced mild side effects like headaches or scalp discomfort, but these effects usually did not last long.

The medications used with cTBS in this trial are all FDA-approved and commonly prescribed. Memantine and d-cycloserine target the glutamate system, while lorazepam and baclofen affect the GABA system. These medications have established safety records from their use in other conditions. While side effects can occur, they are typically mild and temporary.

Most treatments for depression, like SSRIs or psychotherapy, focus on altering neurotransmitter levels over time. However, the treatments being studied here are different because they use Continuous Theta Burst Stimulation (cTBS), a form of transcranial magnetic stimulation (TMS), which can target brain activity more directly and quickly. Researchers are particularly excited about the different combinations of cTBS with drugs like memantine, d-cycloserine, lorazepam, and baclofen. These combinations target specific brain receptors such as NMDAR and GABA, potentially offering faster and more precise relief of depressive symptoms. This innovative approach could lead to more effective and quicker-acting treatments for those who don't respond well to traditional therapies.

Research has shown that continuous theta-burst stimulation (cTBS) can reduce depression symptoms by altering brain function. One study found that cTBS decreases brain activity, potentially calming overactive areas in people with depression. Additionally, cTBS has proven as effective as the standard treatment, repetitive transcranial magnetic stimulation (rTMS), for managing depression symptoms.